Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

AD-VEC

Financiado

Cerrado

Adenovirus Vector Technology Next Generation Systems for Medical Therapy

We propose a programme (AD-VEC) involving two industrial and three academic partners with the aim to identify new adenoviral vectors as vehicles in novel medical applications for cardiovascular disease and infectious disease. This... ver más

28/02/2017

UEDIN

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

THE UNIVERSITY OF EDINBURGH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-02-28 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

UEDIN

0.00€ | Lider

UNIVERSITY OF GLASGOW

N.D. | Participante

UMEA UNIVERSITET

N.D. | Participante

Proyectos interesantes

BFU2013-41249-P

Medical Technol...

Biotechnology

121K€ Cerrado

BIO2015-68990-REDT

Medical Technol...

Nanotechnology

31K€ Cerrado

iAds

Medical Technol...

Biotechnology

3M€ Cerrado

RTI2018-097730-B-I00

Medical Technol...

Genetic Enginee...

121K€ Cerrado

Nueva terapia génica basada en virus adenoaso...

Medical Technol...

Biotechnology

200K€ Cerrado

Nueva terapia génica basada en virus adenoaso...

Medical Technol...

Biotechnology

200K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

THE UNIVERSITY OF EDINBURGH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto We propose a programme (AD-VEC) involving two industrial and three academic partners with the aim to identify new adenoviral vectors as vehicles in novel medical applications for cardiovascular disease and infectious disease. This will be achieved through broad knowledge exchange between partners with complimentary and cutting edge technological and in-depth skills relating to adenovirus phylogeny, biology and pathology in order to explore and exploit adenovirus existing in nature as new vectors in areas of unmet clinical need such as cardiovascular disease and infectious disease. Our major objectives of AD-VEC are: (1) The provision of adenovirus genomes from novel rare human and non-human adenoviruses and engineering of these genomes to develop high quality recombinant adenovirus vectors expressing reporter genes; (2). To provide detailed evaluation of novel adenovirus vectors with respect to infectivity, receptor usage, tropism, and the interaction with the blood and immune system; (3). To evaluate these novel vectors at the pre-clinical level in areas of unmet clinical need, both using in vitro and in vivo studies. These three key objectives will enable excellence in adenovirus research amongst the AD-VEC consortium members through creating a synergistic and unique opportunity in this research field. The synergies are those that cross academic and industrial boundaries and create access to a pipeline of activity that will include basic virology, new assay development, novel preclinical models, pre-clinical manufacture and vector testing. This provides empowerment to the research teams through synergistic industry/academia collaborations developed towards a common goal, i.e. exploiting adenoviruses for medical therapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores